Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Acorda Therapeutics Inc (NASDAQ:ACOR)

34.36
Delayed Data
As of Jul 31
 +0.13 / +0.38%
Today’s Change
28.26
Today|||52-Week Range
45.45
-15.93%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.5B

Company Description

Acorda Therapeutics, Inc. engages in the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the nervous system. The company's two main products are Ampyra and Zanaflex Capsules. The Ampyra is an oral drug, which treats to improve walking in patients with multiple sclerosis and Zanaflex Capsules, which is a short acting drug for the management of spasticity, a symptom of many central nervous system disorders, including multiple sclerosis and spinal cord injury. Acorda Therapeutics was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.

Contact Information

Acorda Therapeutics, Inc.
420 Saw Mill River Road
Ardsley New York 10502
P:(914) 347-4300
Investor Relations:

Employees

Shareholders

Mutual fund holders67.67%
Other institutional45.29%
Individual stakeholders17.81%

Top Executives

Ronald CohenPresident, Chief Executive Officer & Director
David LawrenceChief-Business Operations
Michael W. RogersChief Financial Officer
Andrew R. BlightChief Scientific Officer
Anthony O. CaggianoVice President-Research & Development